Vera Therapeutics to Present at Upcoming Investor Conferences
Vera Therapeutics, a late-stage biotechnology company, announced its participation in two investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vera Therapeutics, a late-stage biotechnology company, announced its participation in two investor conferences. The Piper Sandler 34th Annual Healthcare Conference will feature a presentation on November 29, 2022, from 9:50 to 10:10 AM ET. Additionally, a Fireside Chat is scheduled for December 1, 2022, at the 5th Annual Evercore ISI HealthCONx Conference from 12:10 to 12:30 PM ET. Both sessions will be webcasted, and replays will be accessible for 90 days. Vera is focused on treatments for immunological diseases and is advancing its lead candidate, atacicept.
Details
News Market Reaction – VERA
The recorded move for VERA in the trading session of this news was +3.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at the following investor conferences, as detailed below:
Piper Sandler 34th Annual Healthcare Conference
Format: Presentation
Date and Time: Tuesday, November 29, 2022, 9:50 – 10:10 AM ET
Webcast: https://event.webcasts.com
5th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat
Date and Time: Thursday, December 1, 2022, 12:10 – 12:30 PM ET
Webcast: https://wsw.com/webcast
A replay of the presentations will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Kathy Vincent
Greig Communications, Inc.
kathy@greigcommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.